Van Vliet 1996.

Methods	Study design: Randomised controlled trial
Participants	Diagnosis: DSM‐III‐R panic disorder with or without agoraphobia Method of diagnosis: open interview Age: M = 35, SD = 7.46 Sex: 26 women, 6 men Location: the Netherlands; setting: outpatients Co‐morbidities: patients with another anxiety disorder, major affective disorders or psychotic disorder, alcohol or drug abuse and medical problems were excluded Rescue medication: oxazepam maximum 30 mg daily
Interventions	Participants were randomly assigned to either: (1) brofaromine arm (n = 15) Duration: 12 weeks Treatment Protocol: fixed dosage 150 mg (2) fluvoxamine arm (n = 15) Duration: 12 weeks Treatment Protocol: fixed dosage 150 mg
Outcomes	Time points for assessment: weekly Outcomes: 1. Hamilton Rating Scale for Anxiety (HAMA) 2. Montgomery–Åsberg Depression Rating Scale (MADRS) 3. Fear Questionnaire 4. number of panic attacks 5. Hamilton Rating Scale for Depression (HAM‐D) 6. SCL‐90
Notes	Date of study: not stated Funding source: not stated Declarations of interest among the primary researchers: not stated.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomly".
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "double blind". No further information provided.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "double blind". No further information provided.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No information provided about management of incomplete outcome data.
Selective reporting (reporting bias)	High risk	Continuous outcomes are reported incompletely (number of evaluated patients is not reported), so that they cannot be entered in a meta‐analysis; Fear Questionnaire data for agoraphobia are only reported in graphs.
Other bias	Unclear risk	Sponsorship bias cannot be ruled out.